COMMUNIQUÉS West-GlobeNewswire

Microbot Medical Announces First Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds
16/09/2025
$25.2 million in first closing and $4 million in second closing, with up to an additional approximately $63 million of potential aggregate gross proceeds upon the exercise in full of short-term preferred investment [...]
Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types
16/09/2025
Analyst/Investor event showcases opportunities for KO-2806 (darlifarnib) in combination with PI3Kα inhibitors, KRAS inhibitors and antiangiogenic tyrosine kinase inhibitors (TKIs) Preliminary clinical data and KO-2806 [...]
Cytokinetics Announces Proposed Private Placement of $550.0 Million of Convertible Senior Notes
16/09/2025
SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced its intention to offer, subject to market conditions and other factors, $550.0 [...]
Resmed Announces Participation in the Bank of America Global Healthcare Conference 2025
16/09/2025
SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the Bank of [...]
NurExone Planning to Establish First U.S. Commercial Manufacturing Facility in Indiana
16/09/2025
Secures Incentive Offer of up to US$255K to Establish Operations in Indianapolis TORONTO and HAIFA, Israel and INDIANAPOLIS, Sept. 16, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90 [...]
Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting
16/09/2025
TEL AVIV, Israel, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced plans to present data from the completed phase 3 SOLARIS trial at the 2025 Psych Congress [...]
HealthEx and Epic Lead Patient Access Push on TEFCA
16/09/2025
A major advancement towards a patient-centric health ecosystem SAN FRANCISCO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- HealthEx today announced enhanced interoperability with Epic through the Trusted Exchange Framework and [...]
TOMI Environmental Solutions Appoints Francesco Fragasso to its Board of Directors
16/09/2025
Brings Over 25 years of Global Financial and Operational Leadership Experience Across Multiple Industries FREDERICK, Md., Sept. 16, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: TOMZ), [...]
MULTIMEDIA UPDATE -- Marine Biologics Partners with Molecular Quantum Solutions to Accelerate Next-Generation Biomaterials Development
16/09/2025
BERKELEY, Calif. and COPENHAGEN, Denmark, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Biomaterials company Marine Biologics today announced an exclusive strategic partnership with Molecular Quantum Solutions (MQS) in which [...]
Quetzal Therapeutics Appoints Dr. Shaad Abedin as Chief Medical Officer
16/09/2025
CHICAGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company focused on developing transformative therapies for patients with rare and life-threatening diseases, today announced the [...]
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 37 - 2025
16/09/2025
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 08 Septembre au 12 Septembre 2025 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la [...]
IPSEN - Buy-back programme - Art 5 of MAR - Week 37 - 2025
16/09/2025
Aggregated presentation by day and by market Statement of transactions in own shares from September 08th to September 12th 2025 Name of the issue Identity code of the issuer (Legal Entity Identifier) Day of the [...]
UTR Therapeutics Publishes Landmark Preclinical Data in Frontiers in Pharmacology Supporting IND Submission for First-in-Class c-MYC RNA Therapeutic
16/09/2025
NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- UTR Therapeutics Inc., a biotechnology company advancing a novel RNA Overwriting platform, today announced the peer-reviewed publication of preclinical data in Frontiers in [...]
ZKR Orthopedics Announces First Patella LIFT™ Surgeries on the East Coast at Hospital for Special Surgery in Enrollment of FDA PELICAN Trial
16/09/2025
NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- ZKR Orthopedics announced today that the first Patella LIFT™ procedures on the East Coast were successfully performed as part of the PELICAN TRIAL, at the renowned Hospital [...]
Parexel Announces Appointment of Rob Goodwin as Chief Operating Officer
16/09/2025
Industry veteran brings proven expertise in global clinical development and further strengthens company focus on operational excellence, quality and delivery RALEIGH, N.C., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Parexel, a [...]
Medicines360 acquires global rights to PeriPeach™, advancing new maternal health technology through the 360 Innovation Hub™
16/09/2025
SAN FRANCISCO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Medicines360 , a women’s health innovation organization with a mission to be a catalyst for change, today announced that it has acquired global licensing rights to [...]
Starton Therapeutics Granted New U.S. Patent #12,390,457 Titled “Stable Solutions of Immunomodulatory Imide Compounds for Parenteral Use” a Formulation of STAR-LLD
16/09/2025
New U.S. patent provides IP coverage for the formulation to 2042 Further expands Starton’s intellectual property portfolio surrounding its lead product candidate, STAR-LLD, Method of Use Patent #11,197,852 which [...]
Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04
16/09/2025
FDA Minutes Reflect Constructive Dialogue and Successful Meeting Outcome with Alignment on Upcoming Phase 3 Clinical Trial Design for AD04 In Alcohol Use Disorder GLEN ALLEN, Va., Sept. 16, 2025 (GLOBE NEWSWIRE) -- [...]
CoreHealth Unveils CoreHealth NOW: A Turnkey Employee Wellness Solution for Today’s Workforce
16/09/2025
TORONTO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- CoreHealth, a leading provider of innovative digital health solutions is pleased to announce the release of CoreHealth NOW, a turnkey well-being solution designed to help [...]

Pages